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Background: Mother to child transmission of HIV (MTCT) is a global challenge affecting
many countries especially in sub-Saharan Africa. In 2009 about 370,000 infants were
infected with HIV mainly through MTCT and most of them in sub-Saharan Africa. We
aimed to determine the effectiveness of Option B+ compared to other options in reducing
rates of early MTCT of HIV infections in Zambia.
Methods: This was a retrospective cohort study based on routinely collected data
using SmartCare in Zambia. Survival analysis with Cox Proportional Hazard regression
was used to determine association between MTCT and regimen type of mothers.
Kaplan-Meier (K-M) curves were used to compare MTCT for infants born to mothers
option B+ to those on other options, and Wilcoxon (Breslow) test was used to establish
statistical significance.
Results: Overall (n = 1,444), mother-baby pairs with complete data were included in
the analysis, with the median age of mothers being 33 (28–38) years; and 57% of these
women were on Option B+. MTCT rate was estimated at 5% (73/1,444) [P = 0.025].
A Kaplan-Meier estimate showed that HIV Exposed Infants (HEI) of mothers on Option
B+ had lower MTCT rate than those who were on other MTCT prevention interventions
[Wilcoxon test; chi2 = 4.97; P = 0.025]. Furthermore, The Nelson Aalen cumulative
hazard estimates indicated similar evidence of option B+ being more effective than other
options with some statistical significance [HR = 0.63, P = 0.068]. HEI of option B+
mothers had 50% reduced risk of having HIV infection compared to option A/B [adjusted
HR = 0.4; 95% CI = 0.28–0.84; P = 0.010]. HEI to women who were married had
an increased risk 50% of getting infected compared to those not married [adjusted
HR = 1.5; 95% CI = 3.43–6.30; P < 0.001]. Exposed infants whose mothers had
assisted delivery had 3 times increased risk of getting infected compared to those born
through normal vaginal delivery [Adjusted HR = 3.2; 95% CI = 0.98–10.21; P = 0.050].
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Conclusions: The use of Option B+ as PMTCT intervention was found to be more
effective in reducing MTCT of HIV compared to other options. Scaling up access to
life-long ART and improving retention for women on treatment can potentially reduce
further vertical transmission.
Keywords: PMTCT, pregnant women, option B+, routine data, HEI, Zambia
INTRODUCTION
Mother to child transmission of HIV (MTCT) is a global
challenge affecting many countries especially in Sub-Saharan
Africa. In 2009 about 370,000 infants were infected with HIV
mainly through MTCT with most of them in Sub-Saharan Africa
(1). By 2012, the number of newly infected infants globally
had come down to 260,000 (2, 3) and by 2015, only 150,000
children were newly infected with HIV at birth [(4); UNGASS].
In Zambia, MTCT is one of the key drivers of HIV epidemic
with 10% of all new HIV infections, and 90% of infections in
children attributable to MTCT. Without antiretroviral therapy,
15–30% of babies born to HIV positive women are infected
during pregnancy and delivery, while a further 5–20% become
infected through breastfeeding (4–6). In resource constrained
countries, approximately one third of HIV infected children
die before 1 year and more than half die before their second
year (7–12).
In 2008, 16.4% of women attending antenatal clinic (ANC)
in Zambia were HIV positive, putting 80,000 infants at risk of
getting infected through MTCT (5, 13). The Zambia ministry of
health integrated PMTCT into Maternal and child health (MCH)
to help reduce MTCT of HIV and to decrease both maternal and
childmortality (4, 6). In an effort to further reduceMTCT of HIV,
in 2013 Zambia adopted the World Health Organization (WHO)
guidelines and introduced Option B+ as a new strategy within
the PMTCT program. In the same year, the national PMTCT
program recommended that all infants born to HIV positive
mothers had a virological antigen test for HIV within the first
6 weeks and a second test at 6 months of life. HIV rapid antibody
tests would only be used at the age of 12 and 18 months to
check on the HIV status of the infants (14). Option B+ requires
initiation of all HIV positive pregnant and breastfeeding women
onto lifelong Antiretroviral therapy (ART), regardless of CD4+
cell count or WHO clinical staging.
Before adopting option B+, the Zambian National Guidelines
for PMTCT, updated in 2007–2009, demanded that women
eligible for lifelong combination Antiretroviral Therapy (cART),
option A/B, were those with absolute CD4 count≤350 cells/mm3
(regardless of clinical stage). Option A regimen included AZT
Abbreviations: MTCT, Mother to Child Transmission; PMTCT, Prevention
of mother to Child Transmission; EID, Early Infant Diagnosis; HEI, HIV
Exposed Infants; ANC, Antenatal Care; eMTCT, elimination of Mother to
Child Transmission; ART, Antiretroviral Therapy; cART, Combined Antiretroviral
Therapy; HIV, Human Immuno-Virus; DBS, Dry Blood Sample; DNA PCR,
Deoxyribonucleic Acid Polymerase Chain Reaction; CDC, Centers for Disease
Control and Prevention; UNZABREC, University of Zambia Biomedical Research
Ethics Committee; MOH, Ministry of Health; WHO, World Health Organization.
starting at 14 weeks gestation followed by single dose Nevirapine
(sd-NVP) and AZT/3TC at delivery for 7 days postpartum for
mother and daily NVP from birth until 1 week after breastfeeding
cessation or 4–6 weeks if no breastfeeding or mother on triple
ART for the infant. On the other hand, Option B included Triple
ARV Prophylaxis at 14 weeks gestation and ending at delivery
or 1 week after breastfeeding cessation and Daily NVP or twice
daily AZT for 4–6 weeks when replacement feeding and daily
NVP for 6 weeks when breast feeding. This criteria had a negative
impact on the effectiveness of option A/B regimen because
of resource constraint challenges that included (1) capacity of
health centers to assess CD4 count, (2) availability of CD4
count results at clinics for decision making, and (3) capacity
to initiate cART. One study conducted in Zambia showed that
test results of 33.5% of blood samples collected for CD4 count
were never returned to the clinic. Only a minority of HIV-
positive pregnant women were assessed for CD4 count and had
their test results available. Among HIV-positive women whose
CD4 count results were available, 47% were eligible for cART
due to the cell count threshold of ≤350 cells/mm3. Frequent
breakdown of CD4 count machines, insufficient number of
trained laboratory technicians to run CD4 count laboratory
equipment, lab fees applied in some facilities for CD4 count, and
clerical errors all compounded the problem (4, 5, 15, 16). Women
who were not eligible for lifelong ART were given a short course
of prophylactic treatment designed to protect the infant from
MTCT of HIV (Table 1).
Option B+ initiative started in Malawi in 2011 because of
the country’s high HIV prevalence; short birth intervals (median
= 3 years), high fertility (total fertility rate = 5.7), extended
breastfeeding and a limited laboratory capacity (14, 17, 18).
Zambia shared many of Malawi’s characteristics for MTCT
of HIV. However, there has been great controversy on the
adoption of the option B+ strategy as the best approach to
achieving elimination of mother-to-child-transmission from its
inception in 2011 in Malawi and its adoption in other resource
constraint regions with limited laboratory capacity. This study
aimed to establish the effectiveness of option B+ compared
to other PMTCT interventions and the factors associated with
MTCT. The results will help fill the increasing gap between
established policy on PMTCT strategies, particularly option B+
as an effective approach to reduce HIV transmission and the
social practices associated with program feasibility, accessibility,
uptake, and retention in care.
There is substantial body of literature from elsewhere
on the effectiveness of the PMTCT programme in reducing
transmission from mother to child, but data from Africa
about the operational effectiveness of Option B+ in the
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TABLE 1 | Treatment algorithm and transition of PMTCT strategies in Zambia for HIV positive women and their exposed babies.
Woman Infant
CD4+ Cell count <
350 cells/µl
WHO staging 3 or 4
CD4+ Cell count ≥ 350
cells/µl
WHO staging 1 or 2
Option A ART for Life AZT starting at 14 weeks
gestation
Daily NVP from birth until 1 week after
breastfeeding cessation or 4-6 weeks if
no breastfeeding or mother on triple
ART
sd-NVP and AZT/3TC at
delivery for 7 days postpartum
Option B ART for Life Triple ARV Prophylaxis at 14
weeks gestation and ending
at delivery or 1 week after
breastfeeding cessation
Daily NVP or twice daily AZT for 4–6
weeks when replacement feeding. Daily
NVP for 6 weeks when breast feeding
Option B+ ART for Life ART for Life Daily NVP for 6 weeks
PMTCT are sparse (17, 19–27). Particularly in Zambia the
effectiveness of option B+ has not been evaluated, as far as
we are aware, thereby raising concerns on its effectiveness in
the elimination of MTCT. This study measured the MTCT
rate of HIV on Option B+ compared to other options in




SmartCare is an electronic health management record system
which stores individual patient information at about 600
government health facilities in Zambia. It can be used for
monitoring of patient treatment and outcomes and for reporting
health service delivery at district, provincial and national levels
across all districts of Zambia (14). SmartCare is a public
domain, data system using microchip, touch screen, and solar
technologies to improve health records of patient care and
to enable public health reporting for persons attending health
facilities. It records all patient interactions and subsequent visits
to the health facility which includes clinical appointments,
laboratory and pharmacy data with a unique identification
number. This electronic health record system stores patient
information on a computer, as well as a smart card, and
easily produces reports at facility, district, provincial or national
levels. SmartCare provide greater continuity of clinic based care;
and increases the privacy of sensitive medical information in
services for Family Planning, sexually transmitted infections and
HIV. For pregnant women, SmartCare is used for Ante-natal
clinical visits and enrolment into PMTCT services. SmartCare
aims to reduce the burden of paperwork on health staff and
improve the quality of information and decision support for
patients, while providing automated information flow into the
government’s existing Health Management Information System
(ZHMIS) (28).
Option B+ Effectiveness Design
Sampling and Setting
This was a retrospective cohort study of HIV-infected women
and their infants with data recorded in SmartCare. The Zambia
ART programme has opt-out HIV testing for all eligible pregnant
women, with all women having a positive HIV test result
and those with known positive status be enrolled into the
PMTCT programme. In the PMTCT programme they receive
a comprehensive intervention to prevent MTCT of HIV. Since
2013, all women enrolled into the PMTCT programme are
treated with lifelong ART (option B+) regardless of their CD4
cell count or WHO staging (Zambia Consolidated PMTCT
Guidelines) (see Table 1).
All women enrolled in the PMTCT programme with records
in the SmartCare database between 2007 and 2017 were included
in the study. The outcome was measured in HEI born to women
who were HIV positive.
Data Extraction and Management
Data were abstracted from HIV infected pregnant and
breastfeeding women who were enrolled into PMTCT and
ART registers using SmartCare database between 2007 and 2017.
All records of HEI were paired with the HIV-infected women.
The extracted data included the demographic characteristics of
the pregnant women at enrolment, their entry point through
HIV counseling and testing, history of antenatal care for the
most recent birth, full birth history on labor and delivery, ART
regimen type, mode of delivery, postnatal, and follow up data for
both mother and new-born baby; social-economic status; and
educational attainment.
Statistical Analysis
All analyses were done using Stata software version 14 (Stata
corporation College Station, Texas). Descriptive analysis were
used for the characteristics of the pregnant women and their
babies. The outcome of interest was time to anHIV positive result
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in the babies, with those who tested HIV negative censored at the
date of the negative test.
Using Kaplan-Meier (K-M), graphs were used to show time to
HIV positivity, comparing women with different characteristics.
Survival analysis were done to determine and compare the
rate of transmission between HIV positive pregnant women on
Option B+ compared with those on the other regimen in the
PMTCT program. The Wilcoxon (Breslow) test was used to
establish statistical significance of the difference in the survival
rates between option B+ and other interventions. Both single
and multiple Cox proportional hazards regression models were
conducted to determine the rate of transmission of HIV and
potential confounders of MTCT. The Nelson Aalen cumulative
hazard estimates were used to assess the risk of transmission
between the two regimen. The validity of the proportional hazard
assumptions were assessed using stph-plots for the treatment
regimens. Bivariate analysis using Pearson’s chi squared test was
TABLE 2 | Characteristics of HIV positive women on Lifelong ART (Option B+)
from Zambia SmartCare routinely collected data, 2005–2017.
Characteristic Frequency (%) 95% CI
Age categories (in years)
15–24 123 8.5 [7.2–10.1]
25–34 697 48.3 [45.7–50.9]
35–50 624 43.2 [40.7–45.8]
Marital status
Single 136 9.9 [8.5–11.6]
Married 1,185 86.6 [84.7–88.3]
Divorced/Widowed 47 3.5 [2.6–4.5]
Education level
None/Primary 660 56.2 [53.3–58.9]
Secondary 472 40.2 [37.4–43.0]
Tertiary 43 3.6 [2.6–4.5]
Parity
0–1 710 49.2 [46.6–51.8]
2–4 588 40.8 [38.2–43.3]
5–8 145 10.0 [8.6–11.7]
Delivery mode
Assisted 25 1.8 [1.2–2.6]
Cesarean 18 1.3 [1.0–1.9]
Normal delivery 1,386 96.9 [95.9–97.8]
Current CD4 count
11–349 330 35.0 [32.0–38.1]
350–499 255 27.1 [24.3–30.0]
500–1550 357 37.9 [34.8–41.0]
Had trouble taking pills
No 1,008 98.9 [98.1–99.4]
Yes 11 1.1 [0.6–1.9]
Number of doses missed
0 815 98.6 [97.5–99.2]
1 or more 12 1.4 [0.8–2.5]
Sample size = 1,444.
Median (IQR) age = 33 (28–38) years.
Mean baseline CD4+ cell count = 467 cells/ml (SD 246.5).
95% CI obtained using Pearson chi squared.
used to determine the crude associations between Option B+ and
infant HIV status. The rate of vertical transmission was used as a
proxy to measure effectiveness at a rate of 5% or less according to
WHO universal goal (4).
Ethics Consideration
Permission was sought from Zambia Ministry of Health (MOH)
and Centers for Disease Control Zambia (CDC) to use SmartCare
TABLE 3 | Bivariate analysis of background characteristics and Regimen type of
HIV Positive mothers from Zambia SmartCare routinely collected data,
2007–2017.
Infant HIV status
N = 1,444 Negative Positive
Characteristic Total Frequency (%) Frequency (%) P-Value
Treatment group 0.003*
Option A/B 864 808 [93.5] 56 [6.5]




15–24 123 118 [95.9] 5 [4.1]
25–34 697 651 [94.4] 46 [6.6]
35–50 624 602 [96.5] 22 [3.5]
Marital status <0.001**
Single 136 136 [100.0] 0 [0.0]
Married 1,185 1,125 [94.9] 60 [5.1]
Divorced/Widowed 47 41 [87.2] 6 [12.8]
Education level 0.336**
None/Primary 660 629 [95.3] 31 [4.7]
Secondary 472 446 [94.5] 26 [5.5]
Tertiary 43 39 [90.7] 4 [9.3]
Parity 0.302**
0–1 710 669 [94.2] 41 [5.8]
2–4 588 560 [95.2] 28 [4.8]
5–8 145 141 [97.2] 4 [2.8]
Delivery mode 0.184**
Normal Delivery 1,386 1,316 [95.0] 70 [5.0]
Assisted 25 22 [88.0] 3 [12.0]
Cesarean 18 18 [100.0] 0 [0.0]
Current CD4 count 0.465*
11–349 330 309 [93.6] 21 [6.4]
350–499 255 232 [91.0] 23 [9.0]




No 1,008 954 [94.6] 54 [5.4]




0 815 772 [94.7] 43 [5.3]
1 or more 12 12 [100.0] 0 [0.0]
Sample size = 1,444.
Median (IQR) age = 33 (28–38) years.
Mean baseline CD4+ cell count = 467 cells/ml (SD 246.5).
*P-Values obtained using Pearson chi squared.
**P-Values obtained using Fishers Exact.
Bold values represent a significance of p < 0.2.
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FIGURE 1 | Comparison of survival estimates between exposed infants of HIV positive mothers on option A/B and Option B+. (a) Zambia introduced lifelong Option
B+ for HIV positive mothers mid 2013. (b) Prior to 2013, HIV positive mothers with CD4 count <350 cells/ ml were put on Option A/B.
patient data. A waiver was obtained from the University of
Zambia Biomedical Research Ethics Committee (UNZABREC)
reference Number 010-04-18 which granted permission to
conduct this study on HIV cascade in PMTCT and associated
factors. All SmartCare data had personal identifiers removed to
maintain confidentiality and anonymity of the participants.
RESULTS
Participation and Distribution
A total of 1,444 mother and their infants were matched to the
SmartCare record for their infants and included in the analysis.
The mothers were aged 15–50 years with a Median (IQR) age of
33 (28–38) years. Further, 87% (1,185) were married and 56%
(660) had attained primary education only. In addition, 50%
(710) of the mothers reported a parity of (0–1) whilst 10% (145)
had five or more previous births, but normal vaginal delivery was
reported by almost all 97% (1,386) women.
The mean baseline CD4+ cell count was 467 cells/ml (SD
246.5). Of the total women, 40% (580) had been enrolled
on Option B+, of which only 1.4% (12) reported non-
adherent (Table 2).
HEI of positive mothers on option B+ regimen had a reduced
transmission rate of 2.9% (17/580) compared to other regimen
(P = 0.003). MTCT was higher among the women aged 25–34,
accounting for 7% (46/697) (P = 0.034). Furthermore, married
women had a higher transmission rate of 12% (6/47) compared
to those not married 5% (60/1,125) (P < 0.001). HIV positive
mothers who delivered through assisted means had a higher
likelihood to transmit the Virus to their infant, 12% (3/25)
compared to those with a spontaneous vaginal delivery 5%
(70/1,386) or cesarean section 0% (0/18) (P = 0.184) (Table 3).
Key Predictors for Mother to Child
Transmission of HEI
In the survival analysis, overall, a total follow up time of 38,520
months was experienced by 1,444 children born to HIV positive
mothers. There were 73 recorded HIV positive tests, giving a
MTCT of 5.1 per 100 livebirths. A Kaplan-Meier (K-M) estimate
showed that HIV exposed infants of mothers recruited on option
B+ had lower MTCT than those recruited on the other options.
A Wilcoxon (Breslow) test for equality of survival functions
showed statistical significance (chi2 = 4.95, P = 0.025) for the
observed difference in HIV survival rates between Option B+
and other PMTCT options. Proportional hazard assumptions
were assessed using stph-plots for treatment regimen and
were satisfied.
Furthermore, The Nelson Aalen cumulative hazard
estimates (HR = 0.63, P = 0.025) and the smooth
hazard estimates indicated similar evidence of statistical
significance for a difference in transmission of HIV
between infants exposed to Option B+ and Option A/B
mothers (Figures 1–3).
Exposed infants to HIV positive option B+ mothers had
50% reduced risk of having HIV infection through vertical
transmission compared to those exposed to option A/B mothers
[adjusted HR = 0.4; 95% CI = 0.28–0.84; P = 0.010]. HEI
to option B+ women who were married had an increased
risk 50% of getting infected compared to those exposed
to mothers not married [adjusted HR = 1.5; 95% CI =
3.43–6.30; P < 0.001]. Furthermore, Exposed infants whose
mothers had assisted delivery had 3 times increased risk of
getting infected compared to those who had normal vaginal
delivery [Adjusted HR = 3.2; 95% CI = 0.98–10.21; P =
0.050] (Table 4).
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FIGURE 2 | The Nelson Aalen cumulative hazard estimates for HIV exposed infants by treatment groups.
FIGURE 3 | Smooth hazard estimates for HIV exposed infants by treatment groups.
DISCUSSION
In 2014, the national HIV vertical transmission rate recorded was
at 9% (29). Our current data suggest an HIV transmission rate
of 5%. This finding is actually lower than sub-Saharan average
rate as observed in one cohort study conducted in Ethiopia and
other African countries which showed that out of the 221 live
births fromHIV positivemothers, MTCT rate was approximately
between 8 and 10% (30). The Global eMTCT Plan recommends
providing comprehensive PMTCT services to at least 95% of
pregnant women and reduceMTCT to<5% by the year 2015 and
zero transmission by 2030 (31).
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TABLE 4 | Cox proportional hazard analysis of background characteristics and Regimen type of HIV Positive woman from Zambia SmartCare routinely collected
data, 2018.
Characteristic Unadjusted-HR P-Value 95% CI Adjusted-HR P-Value 95% CI
Treatment group
Option A/B Ref. Ref.
Option B+ 0.4 0.004 0.5 0.010 [0.28–0.84]
Age group (in years)
15–24 Ref.
25–34 1.3 0.531 [0.53–3.39]
35–50 0.6 0.359 [0.24–1.68]
Education level
None/Primary Ref.
Secondary 1.3 0.391 [0.75–2.12]
Tertiary 1.4 0.489 [.51–4.10]
Parity
0–1 Ref.
2–4 0.9 0.527 [0.53–1.39]
5–8 0.4 0.087 [0.15–1.38]
Marital status
Single Ref. Ref.
Married 1.5 <0.001 [3.60–6.65] 1.5 <0.001 [3.43–6.30]
Current CD4 cell count
11–349 Ref.
350–499 1.4 0.256 [0.78–2.55]
500–1550 1.2 0.485 [0.69–214]
Delivery mode
Normal vaginal delivery Ref. Ref.
Assisted delivery 2.1 0.215 [0.65–6.69] 3.2 0.050 [0.98–10.21]
Cesarean 1.7 1.000 [a] 4.0 1.000 [a]
[a] Missing Confidence intervals because of missing standard errors due to stratum with single sampling unit.
The level of HIV testing uptake among ANC women has
substantially increased from the time PMTCT was introduced
in Zambia in 1999. However, failure to attend all clinical
appointments, adherence to treatment for option B+ mothers
contributes to missed opportunities for early infant Diagnosis
(EID), and as a result many are not tested until after 24 months
as observed in this study. Similar findings were observed in a
retrospective follow up study in Sub-Saharan Africa, from 2004
to 2009 on HIV testing of infants ≥18 month, which posed a
challenge as only 896 (10.6%) of infants completed the follow
up HIV testing, of which 106 infants were found to be positive
representing 14.3% vertical transmission rate (30). Among the
key challenges faced in the diagnosis of infants are lack of
training to collect and handle Dry Blood Sample (DBS), results
not collected from central laboratory andmisplacement of results
within the health facility before reaching the mothers. An infant
is presumed HIV uninfected if they had negative DNA PCR
assays at 6 and 14 weeks of age. A child is classified as HIV
uninfected if both antibody tests are negative at or after 18
months. Its only by addressing these challenges that option B+
benefits can be realized.
Several potential limitations to this study were observed.
Firstly, the main limitation was the inability of SmartCare
to link mothers to their infants, which was very crucial for
this study as it affected the sample size. Secondly, Option
B+ (lifelong ART) coverage in Zambia was gradual after its
adoption in 2013 and many of the health facilities were still
using option A/B and this could have reduced the effect of
change. Besides data was available only in facilities that had
SmartCare system active and functional. Another limitation is
that being routinely collected data, critical variables such as
EID, mother-baby pair link, retention patterns, lost to follow
up, and heath care utilization including the frequency of a
patient’s appearance in the ANC records were missing. The
frequency of a patient’s health care utilization could have been
used to adjust for those visiting the heath care facility more
often which would have indicated who experienced the event
more quickly, and thus bias the time-to-event analysis. Despite
these challenges, however, the data provides better estimates on
the effectiveness of option B+. Besides, most of the facilities
affected with option B+ roll-out were mainly in rural areas.
Furthermore, considering that this is one of the first studies,
as we are aware, to document the experience of implementing
option B+ in Zambia which will help accelerate toward a 2030
ambitious goal of zero HIV transmission, we believe this study is
very worthy to be undertaken.
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Option B+ regimen for mothers and infants offers significant
benefits for transmission prevention, maternal health and public
health program delivery. It presents distinct advantages in terms
of transmission prevention to uninfected partners and increased
simplicity potentially improving program feasibility, access,
uptake and cost effectiveness. Despite these benefits, however,
concerns have been raised about the safety of ART exposure to
fetuses and infants as well as adherence challenges for pregnant
and breastfeeding mothers (32). Similar Option B+ benefits were
observed in a cohort comparative study of 102 women on ART
prior to Option B+ to a cohort of 109 women on Option B+
conducted in Malawi, which showed that women on Option B+
had fewer WHO 3/4 conditions, higher CD4 count and lower
mortality compared to those in pre Option B+ (22). This high
mortality and poor health of pre option B+women posed a direct
effect on the health and survival of their infants. This is because
pregnant women with a high viral load and lower CD4 count are
more likely to transmit HIV virus to their new-born babies (33).
Furthermore, in another study, women on option B+ had low
mortality compared to those on CD4 cell count or WHO clinical
stage criterion group. Mortality among the women on option B+
during pregnancy was 0.4% while those enrolled based on CD4
cell count or WHO clinical stage 3/4 criterion recorded mortality
of 3% (17).
Another study conducted on retention of pregnant and
breastfeeding women in Malawi also observed that most women
(83%) starting ARTwith Option B+, over 17%were lost to follow
up in the 6 months period and most of them occurred in the
first 3 months of therapy. The results further showed that option
B+ women who started therapy during pregnancy were 5 times
more likely than pre option B+ women never to return for their
next clinical follow up (34). These results indicate that although
Option B+ therapy possibly had a better outcome, retention of
women in care and lost to follow up especially after delivery
was a challenge. The possible explanation could have been that
women started on option B+ still enjoyed a good measure of
health because of their good immune system, having a high
CD4 cell count and low viral copies, and would not follow up
their clinical appointments and adhere to therapy potentially
increasing the chances of HIV transmission to the infant (22, 33).
Universal access to HIV testing in ANC and 100% linkage to
care and treatment coupled with strategies to improve retention
and adherence to treatment is crucial to further reduce vertical
transmission rate.
CONCLUSION
In Zambia Option B+ has been found to be more effective
in reducing MTCT rates to lower acceptable levels than any
other options thus opening opportunities for scaling up access
to life-long ART and improving retention and contribute to
potentially reduced vertical transmission sustainably. However,
these findings also suggest the need for programmatic efforts
to identify other maternal health survival bottlenecks that could
hamper universal access to PMTCT interventions for all mother-
baby pairs on lifelong ART in poorly accessed groups. This may
include strategies to prevent missing of clinical appointments,
infant post-natal follow up and eventual non-retention. Lastly
but not the least, these findings also indirectly suggest the need
for further integration of ANC services to include innovative
PMTCT interventions as part of a total service package.
RECOMMENDATIONS
Since Early Infant Diagnosis at recommended time is directly
linked to care and treatment, supporting existing Government
measures to retain HIV-infected women in eMTCT programme
in order to improve access to universal HIV treatment and care
among women is key in addressing barriers to increased uptake
of PMTCT. Strengthening HIV testing in ANC especially in rural
health facilities, encouraging women to adhere to treatment and
attend all clinical appointments as well as providing initiatives
that seek to overcome barriers to treatment are some of the
ways that can help improve maternal and new-born health.
Furthermore, health workers should ensure that HIV-infected
women, on option B+ are retained in care and bring their babies
for clinical appointments and testing at recommended schedules.
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